Home › Liver Diseases › Ohio › Parma
Liver Diseases clinical trials in Parma, OH
3 studies for Liver Diseases are looking for participants at sites in and around Parma (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
- Clinical Research Institute of Ohio (CRIOH), LLC, Westlake · 11 mi away
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Westlake · 11 mi away
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Westlake · 11 mi away
About Liver Diseases
Get the facts about liver diseases, such as hepatitis, cancer, and cirrhosis. Know your risk and what you can do to prevent liver problems.
More about Liver Diseases on MedlinePlus
Liver Diseases trials in other cities
- Houston, TX10 studies
- Chicago, IL9 studies
- Washington, DC8 studies
- Los Angeles, CA7 studies
- Atlanta, GA7 studies
- Richmond, VA6 studies
- New York City, NY6 studies
- San Antonio, TX6 studies
- Philadelphia, PA6 studies
- Durham, NC5 studies
- Dallas, TX5 studies
- Ann Arbor, MI5 studies
Other studies in Parma
- Ulcerative Colitis10 studies
- Crohn's Disease8 studies
- Steatotic Liver Disease7 studies
- Psoriatic Arthritis6 studies
- Lung Cancer5 studies
- Major Depressive Disorder5 studies
- Schizophrenia5 studies
- Endometrial Cancer4 studies
- Non-Small Cell Lung Cancer4 studies
- Ovarian Cancer4 studies
- Inflammatory Bowel Disease4 studies
- Alzheimer's Disease4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.